Home > Boards > US Listed > Medical - Drugs >

BioPharmX Corp. (BPMX)

Add BPMX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/4/2021 12:08:53 PM - Followers: 110 - Board type: Free - Posts Today: 0


Biodelivery that makes a difference! 

BioPharmX Corporation was created to fulfill the unmet medical needs of people worldwide. To achieve that, we take a disciplined approach to research and product development. Our scientists, researchers, marketers and other team members are mission driven, committed to producing novel treatments to cure intractable medical conditions.

We focus exclusively on dermatological issues and women’s health. We seek to develop therapeutic products that provide unique solutions to common medical problems in these areas. Our approach is to create novel mechanisms to deliver effective treatments for persistent and often debilitating conditions.

In dermatology, for example, we are developing a unique way to deliver acne-fighting medicine topically. Today’s most effective acne medications must be ingested, risking undesirable side-effects. Topical treatments tend to be ineffective because their formulations do not deliver medication to the layer of skin where acne forms. Our developmental topical, called BPX-01, effectively delivers small amounts of antibiotic to the acne source, maximizing treatment effectiveness and reducing side-effects.

In women’s health, we are currently focused on improving breast health by treating fibrocystic breast condition, a medical problem that affects half the world’s women. The condition, which often produces breast tenderness and tissue density, can be treated with molecular iodine, which is effective but rarely found in a stable form. Our solution is Violet® iodine, a daily supplement that produces molecular iodine within the body – exactly where it can be most effective.

Both of these solutions demonstrate the power of BioPharmX’s unique combination of innovation and determination.

We develop unique health and wellness products for licensing and commercialization in pharmaceutical and over-the-counter use.



By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.


Violet Iodine
A revolution in women’s breast health.

It’s a daily regimen that alleviates the symptoms you experience with your monthly cycle – like breast tenderness, aches, heaviness and swelling*. Violet iodine doesn’t just mask the discomfort temporarily; it actually promotes better breast health*. When you take a simple pill every day the result is true relief and reassurance that you’re proactively taking care of your breasts.

BioPharmX aims to be a leader in its understanding of the science of the skin.

Currently in phase 2 of clinical development, BPX-01 may offer a breakthrough in acne treatment because it can deliver the antibiotic to the area of the skin where acne develops. The novel hydrophilic (non oil-based) formulation of minocycline may be more effective than other topical alternatives because they either use less effective antibiotics to penetrate the top layer of the skin or rely on higher concentrations of minocycline, which could lead to unpleasant side effects.

BPX-01 is the first and only stable hydrophilic topical gel with fully solubilized minocycline. Minocycline, an antibacterial and anti-inflammatory medicine, is the most commonly prescribed acne treatment because it has a lower resistance rate than other antibiotics. No stable form of hydrophilic topical minocycline is currently commercially available.

  Delivery Pathways

  BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.


Product Types

Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.

Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.


            Over the Counter Products        


With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products. 


BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:

♦ Customized solutions to fit drug formulation needs
♦ Expertise in regulatory, toxicology and clinical studies
♦ Streamlined pathways through development
♦ Unrivaled commitment to quality





BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.




Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.


"Biopharmx's first product violet will hit market this fall"
"This company is a $$ maker." 




BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.



Management Team

The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.



Jim Pekarsky     Resigned , effective May 11, 2016                                                                                                                     

Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.


Anja Krammer                                                                                                                                    

A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.

Kin F. Chan, Ph.D.                                                                                                                             

Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.

Douglas Thomas, Ph.D.                                                                                                                     

Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.

Jack Kessler, Ph.D.                                                                                                                           

Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.

AnnaMarie Daniels                                                                                                                             

Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.

Ross Portaro                                                                                                                                     

Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
Stephen Morlock                                                                                                                                    
A seasoned financial executive and retail industry veteran, has been added to its board of directors.  Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.

Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army.  He served as controller there from 1992 to 1994.  He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.   

"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation.  "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."

Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University


Corporate Headquarters

BioPharmX, Inc.
1098 Hamilton Court
Menlo Park, CA 94025

SEC Filings link below.

OneMed San Francisco 2014 Webcast http://www.onemedplace.com/onemedtv/play.php?vid=2570

2015 Second Quater Finacial Results Webcast http://78449.choruscall.com/dataconf/productusers/bpmx/media/bpmx150914a.mp3








Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3061   sorry wrong board,all my posts 81vette 01/04/21 12:08:53 PM
#3060   rees> Brazil Minerals has now direct ownership of 81vette 01/04/21 11:29:53 AM
#3059   "Lithium is in high demand worldwide and Brazilian 81vette 01/04/21 11:28:03 AM
#3058   97,958 acres of some best gold areas of brazil 81vette 01/04/21 11:15:31 AM
#3057   news today https://www.otcmarkets.com/stock/BMIX/news/story?e&id=1775882 81vette 01/04/21 11:10:06 AM
#3056   macd rising,could run again 81vette 01/04/21 11:01:31 AM
#3055   they are out of shares to dilute,want to 81vette 01/04/21 10:56:25 AM
#3054   hello congrats on GAXY take a look into MakinBank 12/29/20 01:38:54 PM
#3053   I don't know but these two companies were darron427 05/20/20 09:08:45 PM
#3052   How much better could it possibly get after PNW_Ironman 05/20/20 08:58:26 PM
#3051   What's to expect on conference call next Tues? Macca1967 05/20/20 08:26:51 PM
#3050   Anybody get TMBR on the drop ? It's darron427 05/19/20 10:16:28 AM
#3049   And I[m not one to tell other people darron427 05/18/20 03:18:41 PM
#3048   Too good of a stock to be selling darron427 05/18/20 03:16:54 PM
#3047   Yea, it'll be interesting to see what happens bc5ts 05/18/20 03:12:48 PM
#3046   Closing in on .52 real fast..~ darron427 05/18/20 03:09:40 PM
#3045   Timber LOL!!! BluSkies 05/18/20 02:17:20 PM
#3044   It's back over .50.. darron427 05/18/20 12:17:01 PM
#3043   Should I buy in now? Macca1967 05/18/20 12:15:08 PM
#3041   Does anyone know if it is true or Macca1967 05/18/20 12:13:49 PM
#3040   Anybody get in on the bounce.. It's leaving darron427 05/18/20 12:10:33 PM
#3039   Bounce coming! darron427 05/18/20 12:01:21 PM
#3038   Cheap as it's going to get any time darron427 05/18/20 11:13:47 AM
#3037   Notice how they evened that out to .50 darron427 05/15/20 05:44:23 PM
#3036   Only wish I had bought a lot more darron427 05/15/20 04:27:01 PM
#3035   Thanks. What would be the starting price after r/s? Mushimushi78 05/15/20 12:40:12 PM
#3034   Yes you will get shares of TMBR. but brandmcs5211 05/15/20 09:04:52 AM
#3033   you still in $cbdl cspratt15139 05/14/20 09:50:29 PM
#3032   Nice $Pistol Pete$ 05/14/20 08:30:12 PM
#3031   * * $BPMX Video Chart 05-14-2020 * * ClayTrader 05/14/20 04:22:23 PM
#3030   Bouncing! Heading for NHOD! krisc62 05/14/20 01:44:46 PM
#3029   After the merger, do we get shares from tmbr? Mushimushi78 05/14/20 01:32:52 PM
#3028   Possible monster Power hr? Richey75 05/14/20 12:36:23 PM
#3027   Priced in. Zero shorts. Nothing to move it really... Full Contact Yoga 05/14/20 12:21:51 PM
#3026   Big merger but it’s not moving Mushimushi78 05/14/20 12:13:44 PM
#3025   Aka it’s selling off Triple nickle 05/14/20 10:46:45 AM
#3024   Check dcar another reverse merger play will double akamaii 05/14/20 10:24:56 AM
#3023   Massive shorts here will cover fuels the run soon. powerbattles 05/14/20 10:08:48 AM
#3022   Merge done here stock on fire bro. powerbattles 05/14/20 10:07:44 AM
#3021   Aye aye, grabbed some more RarityLovesAll 05/14/20 10:07:29 AM
#3020   $BPMX This merge will move bpmx above one dollar powerbattles 05/14/20 10:06:52 AM
#3019   Ayeeeee RarityLovesAll 05/14/20 10:03:35 AM
#3018   MERGE NEWS! powerbattles 05/14/20 10:00:33 AM
#3017   They vote today so something must be good! powerbattles 05/14/20 09:50:41 AM
#3016   looking better and better Tduggylolz 05/12/20 11:21:49 AM
#3015   $BPMX break this wall at 52 we got Tduggylolz 05/12/20 10:06:44 AM
#3014   pullin up off that 200 dma $BPMX Tduggylolz 05/12/20 10:04:13 AM
#3013   * * $BPMX Video Chart 05-11-2020 * * ClayTrader 05/11/20 05:36:37 PM
#3012   what news? you mean the news that PNW_Ironman 05/11/20 02:50:56 PM
#3011   Seems it’s gonna run end of day type akamaii 05/11/20 01:59:21 PM
Consent Preferences